A Clinical Trial With SENS-601, Injected With SPHYNX Administration System, in the Pediatric Population Presenting With Hearing Loss Related to Pathogenic Variation(s) of GJB2 Gene (HEARCONNEX)
An Open-Label, Multicenter Phase 1/2 Study to Assess the Safety, Tolerability, and Efficacy of Intracochlear Ascending Dose Injections of SENS-601 Followed by Expansion Cohort in Pediatric Population With Hearing Loss Related to Biallelic Pathogenic Variation(s) of GJB2, As Well As to Demonstrate the Performance of the Administration System, Its Safety, Its Clinical Benefit, and Its Usability
This study intends to assess safety, tolerability, and efficacy of SENS-601, injected with SPHYNX administration system, in children between 6 months and 6 years of age, with hearing loss related to pathogenic variation(s) of GJB2 gene.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Lionel HOVSEPIAN
- Phone Number: +33(0)686 831 180
- Email: contact@sensorion-pharma.com
Study Locations
-
-
-
Paris, France, 75015
- Recruiting
- Hopital Necker Enfants Malades
-
Contact:
- Centre de Recherche en Audiologie pédiatrique
- Phone Number: +33(0)187 892 916
- Email: rdv.crea.nck@aphp.fr
-
Principal Investigator:
- Natalie LOUNDON
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males or females aged ≥6 months to ≤6 years.
- Congenital bilateral severe sensorineural hearing loss.
- Biallelic GJB2 variation(s).
- Documented normal cochlea and internal auditory canals.
Exclusion Criteria:
- History of chronic, acute, or major disease.
- Have been dosed in a previous gene therapy clinical study.
- Other causes or risk of hearing loss, including developmental disorders, unilateral hearing loss, chronic conductive hearing loss, malformation syndrome, syndromic hearing loss or any other cause that would impact negatively the response of hair cell function, history of therapy known as ototoxic for an extended period, or documented other causes of congenital bilateral hearing loss linked to mutations in genes other than GJB2.
- Prior or current cochlear implant in the ear to be treated with SENS-601.
- Contraindication to corticosteroid therapy and/or immunosuppressive or immunomodulatory therapy or to the planned surgery, to anesthesia or increased anesthesiologic risk.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Dose escalation - Dose Level 1
Intracochlear administration of Dose level 1 of SENS-601 in one ear, with the SPHYNX injection system |
Administration of SENS-601 with the SPHYNX injection system |
|
Experimental: Dose escalation - Dose Level 2
Intracochlear administration of Dose level 2 of SENS-601 in one ear, with the SPHYNX injection system |
Administration of SENS-601 with the SPHYNX injection system |
|
Experimental: Dose expansion group
Intracochlear administration of SENS-601 in both ears, with the SPHYNX injection system, at the dose recommended following the Dose escalation phase |
Administration of SENS-601 with the SPHYNX injection system |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety and tolerability of SENS-601 and SPHYNX administration system
Time Frame: 5 years
|
The incidence and severity of Treatment-Emergent Adverse Events (TEAEs). The incidence and severity of Adverse Device Events, Serious Adverse Device Effects, and Device Deficiencies |
5 years
|
|
Efficacy of SENS-601 assessed by ABR
Time Frame: 5 years
|
Change from baseline of hearing threshold measured by auditory brainstem response (ABR) |
5 years
|
|
Efficacy of SENS-601 assessed by PTA
Time Frame: 5 years
|
Change from baseline of hearing threshold measured by pure-tone audiometry (PTA) |
5 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
SPHYNX Injection system performance
Time Frame: Day 1
|
Incidence of successful administrations, based on user questionnaires |
Day 1
|
|
SPHYNX Injection System clinical benefit
Time Frame: Day 1
|
Incidence of failed surgeries due to SPHYNX injection system, based on "SENS-601 injection form" user questionnaires |
Day 1
|
|
Usability of the administration system
Time Frame: Day 1
|
Evaluation of the degree to which users were able to effectively, efficiently, and safely use the devices in their specific environments, based on "Usability assessment" user questionnaire |
Day 1
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SENS-601-101
- 2026-525698-38-00 (Ctis)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.